Pirfenidone Attenuates Renal Tubulointerstitial Fibrosis through Inhibiting miR-21

Liangliang Bi1, Yanjie Huang1,2, Jing Li1

  • 1Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.

Nephron
|November 1, 2021
PubMed
Abstract

Insights

Pirfenidone (PFD) reduces tubulointerstitial fibrosis (TIF) in rats by inhibiting microRNA-21 (miR-21) and activating Smad7, thereby blocking the TGF-β1/Smad3 pathway. This study confirms PFD

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Previous studies indicated pirfenidone (PFD) improves tubulointerstitial fibrosis (TIF) and inhibits microRNA-21 (miR-21) in unilateral urethral obstruction (UUO) rat models.
  • Tubulointerstitial fibrosis is a common pathological feature in chronic kidney diseases.

Purpose of the Study:

  • To investigate the mechanism by which PFD attenuates TIF in UUO rats, specifically focusing on the role of miR-21.
  • To compare the effects of PFD and olmesartan (Olm) on TIF and related molecular pathways.

Main Methods:

  • Rats were subjected to UUO and treated with PFD or Olm.
  • Real-time quantitative PCR and automated capillary Western blotting were used to measure miR-21, TGF-β1, Smad3, Smad7, collagen III, E-cadherin, and α-SMA expression.
  • In vitro experiments with miR-21-overexpressing NRK-52E cells were conducted.

Main Results:

  • PFD and Olm both ameliorated renal structural damage and fibrosis compared to the UUO group.
  • PFD treatment downregulated miR-21 and upregulated Smad7, inhibiting the TGF-β1/Smad3 pathway.
  • miR-21 overexpression in vitro promoted epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) accumulation.

Conclusions:

  • PFD attenuates TIF in UUO rats by downregulating miR-21 and upregulating Smad7, subsequently inhibiting the TGF-β1/Smad3 signaling pathway.
  • PFD offers a therapeutic strategy for TIF by targeting the miR-21/Smad7 axis.